These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 27716734)

  • 21. Reduced hepatitis B virus (HBV)-specific CD4+ T-cell responses in human immunodeficiency virus type 1-HBV-coinfected individuals receiving HBV-active antiretroviral therapy.
    Chang JJ; Wightman F; Bartholomeusz A; Ayres A; Kent SJ; Sasadeusz J; Lewin SR
    J Virol; 2005 Mar; 79(5):3038-51. PubMed ID: 15709024
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dendritic cell-based therapeutic vaccine elicits polyfunctional HIV-specific T-cell immunity associated with control of viral load.
    Lévy Y; Thiébaut R; Montes M; Lacabaratz C; Sloan L; King B; Pérusat S; Harrod C; Cobb A; Roberts LK; Surenaud M; Boucherie C; Zurawski S; Delaugerre C; Richert L; Chêne G; Banchereau J; Palucka K
    Eur J Immunol; 2014 Sep; 44(9):2802-10. PubMed ID: 25042008
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preserving HIV-specific T cell responses: does timing of antiretroviral therapy help?
    Macatangay BJ; Rinaldo CR
    Curr Opin HIV AIDS; 2015 Jan; 10(1):55-60. PubMed ID: 25389805
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hitting HIV where it hurts: an alternative approach to HIV vaccine design.
    Altfeld M; Allen TM
    Trends Immunol; 2006 Nov; 27(11):504-10. PubMed ID: 16997629
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immune activation during acute HIV infection and the impact of early antiretroviral therapy.
    Krebs SJ; Ananworanich J
    Curr Opin HIV AIDS; 2016 Mar; 11(2):163-72. PubMed ID: 26599167
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dispelling myths and focusing on notable concepts in HIV pathogenesis.
    Levy JA
    Trends Mol Med; 2015 Jun; 21(6):341-53. PubMed ID: 25883070
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman Primates.
    García-Arriaza J; Perdiguero B; Heeney JL; Seaman MS; Montefiori DC; Yates NL; Tomaras GD; Ferrari G; Foulds KE; Roederer M; Self SG; Borate B; Gottardo R; Phogat S; Tartaglia J; Barnett SW; Burke B; Cristillo AD; Weiss DE; Lee C; Kibler KV; Jacobs BL; Wagner R; Ding S; Pantaleo G; Esteban M
    J Virol; 2017 May; 91(9):. PubMed ID: 28179536
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [HIV/AIDS vaccines: heading for new vaccine approaches?].
    Girard MP
    Bull Soc Pathol Exot; 2008 Jun; 101(3):220-6. PubMed ID: 18681215
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Suppression of HIV replication in the resting CD4+ T cell reservoir by autologous CD8+ T cells: implications for the development of therapeutic strategies.
    Chun TW; Justement JS; Moir S; Hallahan CW; Ehler LA; Liu S; McLaughlin M; Dybul M; Mican JM; Fauci AS
    Proc Natl Acad Sci U S A; 2001 Jan; 98(1):253-8. PubMed ID: 11136258
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Influence of lifelong cumulative HIV viremia on long-term recovery of CD4+ cell count and CD4+/CD8+ ratio among patients on combination antiretroviral therapy.
    Seng R; Goujard C; Krastinova E; Miailhes P; Orr S; Molina JM; Saada M; Piroth L; Rouzioux C; Meyer L;
    AIDS; 2015 Mar; 29(5):595-607. PubMed ID: 25715104
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A case for preART-adjusted endpoints in HIV therapeutic vaccine trials.
    Huang Y; Zhang L; Jolliffe D; Hovden AO; Ökvist M; Pantaleo G; Sommerfelt MA
    Vaccine; 2016 Mar; 34(10):1282-8. PubMed ID: 26826543
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Loss of viral control in early HIV-1 infection is temporally associated with sequential escape from CD8+ T cell responses and decrease in HIV-1-specific CD4+ and CD8+ T cell frequencies.
    Oxenius A; Price DA; Trkola A; Edwards C; Gostick E; Zhang HT; Easterbrook PJ; Tun T; Johnson A; Waters A; Holmes EC; Phillips RE
    J Infect Dis; 2004 Aug; 190(4):713-21. PubMed ID: 15272399
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multiple Approaches for Increasing the Immunogenicity of an Epitope-Based Anti-HIV Vaccine.
    Rosa DS; Ribeiro SP; Fonseca SG; Almeida RR; Santana VC; Apostólico Jde S; Kalil J; Cunha-Neto E
    AIDS Res Hum Retroviruses; 2015 Nov; 31(11):1077-88. PubMed ID: 26149745
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interruption of antiretroviral therapy initiated during primary HIV-1 infection: impact of a therapeutic vaccination strategy combined with interleukin (IL)-2 compared with IL-2 alone in the ANRS 095 Randomized Study.
    Goujard C; Marcellin F; Hendel-Chavez H; Burgard M; Meiffrédy V; Venet A; Rouzioux C; Taoufik Y; El Habib R; Beumont-Mauviel M; Aboulker JP; Lévy Y; Delfraissy JF;
    AIDS Res Hum Retroviruses; 2007 Sep; 23(9):1105-13. PubMed ID: 17919105
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antiretroviral therapy-induced dominant interleukin-2 HIV-1 Gag CD4+ T cell response: evidence of functional recovery of HIV-1-specific CD4+ T cells.
    Tsalimalma K; Kordossis T; Choremi-Papadopoulou E
    Scand J Immunol; 2011 Mar; 73(3):256-65. PubMed ID: 21204901
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New paradigms for generating effective CD8+ T cell responses against HIV-1/AIDS.
    Ahlers JD; Belyakov IM
    Discov Med; 2010 Jun; 9(49):528-37. PubMed ID: 20587342
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A lower viral set point but little immunological impact after early treatment during primary HIV infection.
    Spits HB; Grijsen ML; Steingrover R; Nanlohy NM; Kootstra N; Borghans JA; van Baarle D; Prins JM; Schellens IM
    Viral Immunol; 2015 Apr; 28(3):134-44. PubMed ID: 25746670
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Virologic and immunologic effects of adding maraviroc to suppressive antiretroviral therapy in individuals with suboptimal CD4+ T-cell recovery.
    Cillo AR; Hilldorfer BB; Lalama CM; McKinnon JE; Coombs RW; Tenorio AR; Fox L; Gandhi RT; Ribaudo H; Currier JS; Gulick RM; Wilkin TJ; Mellors JW
    AIDS; 2015 Oct; 29(16):2121-9. PubMed ID: 26544577
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HIV-1-infected children on HAART: immunologic features of three different levels of viral suppression.
    Zaccarelli-Filho CA; Ono E; Machado DM; Brunialti M; Succi RC; Salomão R; Kallás EG; de Moraes-Pinto MI
    Cytometry B Clin Cytom; 2007 Jan; 72(1):14-21. PubMed ID: 17041945
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CD8(+) T cells in preventing HIV infection and disease.
    McDermott AB; Koup RA
    AIDS; 2012 Jun; 26(10):1281-92. PubMed ID: 22441256
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.